Transcript Overview of the research activities in Infectious Diseases in FP7 and

The EU Framework Programme for Research and Innovation
HORIZON 2020
OVERVIEW OF RESEARCH ACTIVITIES
IN INFECTIOUS DISEASES
OCTA - European Parliament
20th October 2015
Inmaculada Peñas Jiménez
'Fighting Infectious Diseases and
Global Epidemics
DG Research & Innovation
European Commission
1
The role of the European Commission Research and innovation
Develop and implement the European research and innovation policy agreed
by the European Parliament and European Council.
Funds research through multi-annual framework programmes for research
(since 1984).
Implemented through annual work programmes and call for proposals and
independent peer review of proposals.
The European Commission manages about 5% of total public
spending in R&D in the European Union.
2
Key priorities for infectious diseases in the
Health, Demographic Change and Wellbeing
Theme
• Emerging infectious diseases (EE)
Influenza and other emerging diseases (incl
vector-borne diseases)
• Anti-microbial resistance (AMR)
• Poverty-related diseases (PRD)
HIV/AIDS, Tuberculosis, Malaria
• Neglected Infectious diseases (NID)
3
Some figures of the research
in major infectious diseases
funded by the FP7 (2007-2013)
4
Some FP7 projects…
• IDAMS
€ 6 million EU contribution - Start 01/09/2011 - 60 months
•
Is improving clinical and laboratory diagnosis and clinical management of dengue;
identifying markers to differentiate dengue from other febrile illness; likelihood to
evolve to a more severe disease; risk of dengue spread and maps; and developing
effective and affordable early warning systems and outbreak responses
•
18 participants from 14 countries including from Mexico,Malaysia and Ghana
• DENGUETOOLS
€ 6 million EU contribution - Start 01/09/2011 - 54 months
•
Developing early diagnostic tests, laboratory-based early warning systems, predictive
models and risk maps better surveillance as well as developing a community-based
strategy to reduce dengue incidence in school aged children
•
15 participants from 11 countries including Brasil, Sri Lanka and Singapore
• DENFREE
€ 6 million EU contribution - Start 01/01/2012 - 60 months
•
Is identifying the key factors determining transmission, outcome of infection and
epidemics of dengue fever, as well as developing of novel diagnostic tools to detect
asymptomatic infections, and estimating the risk of virus spreading to uninfected
areas
•
15 participants from 11 countries including Cuba, Cambodia and French Polynesia
5
What is Horizon 2020?
The EU’s 2014-20 programme
for research & innovation
A core part of Europe 2020,
Innovation Union &
European Research Area
− Responding to the economic crisis to invest in
future jobs and growth
− Addressing people’s concerns about their
livelihoods, safety and environment
− Strengthening the EU’s global position in
research, innovation and technology
http://ec.europa.eu/research/horizon2020
6
HORIZON 2020 (2014-2020)
•
•
•
•
European Research Council
Future and Emerging Technologies
Marie Skłodowska-Curie actions
Research infrastructures
•Excellent
science
•
•
•
Leadership in
enabling and
industrial
technologies
Access to risk
finance
Innovation in
SMEs
•Industrial
leadership
•Societal
challenges
SC1- Health,
demographic changes
and wellbeing
(€ 7.5 b)
The new EU programme for research and innovation
€ 79 billion (2014-2020)
Excellent science €24bn
Health inMarie
H2020
Skłodowska
Future and
Emerging
Technologies
European Research
Council
Curie
Research
Infrastructures
Industrial leadership €17bn
Fast Track to
Innovation
Eureka Eurostars-2
LEIT Biotech
Financial
instruments
SC1 Health €7.5bn (of €31bn)
SME
instrument
IMI-2
Collaborative
projects
AAL-2
EDCTP-2
8
Infectious Diseases R&I – Collaboration for
innovative solutions – Implementation
1 – Collaborative research projects

Implemented by DG RTD
2 - Horizon prize

Implemented by DG RTD
3 – Global Initiatives
 GLOPID- R ; GTBVP; World RePORT
4- Public–Private partnership

IMI2: From discovery to human testing to regulatory
aspects, HTA and pharmacovigilence
5- Public–Public partnership
 EDCTP2
 Joint Programme on AMR
 ERA-INFECT
6- Infectious Disease Finance Facility – INNOVFIN ID
jointly developed by EC and EIB
9
Infectious diseases in Horizon 2020
COLLABORATIVE RESEARCH
Priorities addressed in 2014-2015:
• Vaccine development for poverty related and neglected infectious diseases
• 2014 – Tuberculosis € 25 million – 2 projects funded
• 2015 – HIV/AIDS
€ 45 million – 2 projects funded
•
2014 – COMPARE - Development of web based system for rapid
identification, containment and mitigation of emerging infectious diseases
and foodborne outbreaks by generation and comparison of genomic
information on samples and pathogens across sectors, time and locations,
with contextual additional data.
•
2014 - I-MOVE+,a scientific public health platform to identify, pilot test, use
and disseminate the best study designs to measure the effectivenes (direct
effect)and the impact (indirect and overall effect) of influenza and
pneumococcal vaccines
10
The challenges
• Ageing population
• Increased disease burden
• Unsustainable and unequal
health & care systems
• Health & care sector under
pressure to reform
11
Who's eligible for funding?
•
Horizon 2020 is open to participation from across the
world
•
By default:
•
•
Member States (including overseas departments and
overseas territories)
•
Associated Countries
•
exhaustive list of countries in annex to work
programme (but: no longer BRIC + Mexico in this list!)
Participants from other countries are funded in
exceptional cases:
•
when provision is made in the call text
•
bilateral agreement (e.g. USA, Health challenge – NIH)
•
when the Commission deems it essential (case by case
assessment)
12
The Horizon 2020 Health Challenge:
WP 2016-2017
Understanding health, well-being & disease
Preventing disease
Treating and managing diseases
'Personalised
Medicine'
Active ageing and self-management of health
Methods and data
Health care provision and integrated care
'coordination
activities'
ERA-NETs , Joint Programming, Global Alliance
for Chronic Diseases (GACD), Valorisation of FP7
results and other Coordination Actions
€ 930
million
13
Understanding the call topics: example
• 'PHC 2 – 2015'
• 'Specific
challenge'
• 'Scope'
• 'Expected impact'
• 'Type of action'
14
Topics 2016-2017 - 1.1 Understanding health, wellbeing and disease:
• PM 01 – 2016 – Multi omics for personalised
therapies [RTD]
• PM 02 – 2017- New concepts in patient
stratification [RTD]
• PM 03 – 2016 – Diagnostic characterisation of rare
diseases
• PM 04 – 2016 - Networking and optimising the use
of population and patient cohorts at EU level
[RTD]
15
Topics 2016-2017 - 1.2 Preventing diseases:
• PM-05–2016:
The European Human Biomonitoring
Initiative [RTD]
• PM-06–2016:
Vaccine development for malaria
and/or neglected infectious diseases [RTD]
• PM-07–2017:
young
Promoting mental well-being in the
16
Topics 2016-2017 - 1.3 Treating and managing diseases :
• PM 08 – 2017 - New therapies for rare diseases [RTD]
• PM 09 – 2016 - New therapies for chronic diseases
[RTD]
• PM 10 – 2017 - Comparing the effectiveness of existing
healthcare interventions in the adult population [RTD]
• PM 11 – 2016+2017 - Clinical research on regenerative
medicine [RTD]
17
Topics 2016-2017 - 1.4 Active ageing and self-management of
health:
• PM 12 – 2016 – PCP – eHealth innovation in empowering the
patient [CNECT]
• PM 13 – 2016- PPI for deployment and scaling up of ICT
solutions for active and healthy ageing [CNECT]
• PM 14 – 2016 – EU-Japan cooperation on Novel ICT Robotics
based solutions for active and healthy ageing at home or in
care facilities [CNECT]
• PM 15 – 2017 - Personalised coaching for well-being and care
of people as they age [CNECT]
18
Topics 2016-2017 - 1.5 Methods and data:
• PM 16 - 2017- In-silico trials for developing and assessing
biomedical products [CNECT]
• PM 17 – 2017 - Personalised computer models and in-silico
systems for well-being [CNECT]
• PM 18 – 2016 - Big Data supporting Public Health policies
[CNECT]
• PM 19 – 2017 - PPI for uptake of standards for the exchange
of digitalised healthcare records [CNECT]
• PM 20 - Development of new methods for improved economic
evaluation and efficiency measures in the health sector [RTD]
1.6 Health care provision and integrated care:
• PM 21 - 2016- Implementation research for scaling-up of
evidence based innovations and good practice in Europe and
middle-income countries [RTD]
19
Topics 2016-2017 - Coordination activities:
•
HCO 01 – 2016 - Valorisation of FP7 Health and H2020 SC1 research
results [RTD]
•
HCO 02 – 2016 - Standardisation of pre-analytical and analytical
procedures for in vitro diagnostics in personalised medicine [RTD]
•
HCO 03 – 2017 - Implementing the Strategic Research Agenda on
Personalised Medicine [RTD]
•
HCO 04 – 2016 - Towards globalisation of the Joint Programming
Initiative on Antimicrobial resistance [RTD]
•
HCO 05 – 2016 - Coordinating personalised medicine research [RTD]
•
HCO 06 – 2016 - Towards an ERA-NET for building sustainable and
resilient health care models
•
HCO 07– 2017 - Global Alliance for Chronic Diseases (GACD) [RTD]
•
HCO 08 – 2017 - Actions to bridge the divide in European health
research and innovation [RTD]
20
Topics 2016-2017 Co-ordination activities:
•
HCO 09 – 2016 - EU m-health hub including evidence for the
integration of mHealth in healthcare systems [CNECT]
•
HCO 10 – 2016 - Support for Europe’s leading Health ICT SMEs
[CNECT]
•
HCO 11– 2016 - Coordinated Action to support the recognition of
Silver Economy opportunities arising from demographic change
[CNECT]
•
HCO 12 – 2016 - Digital health literacy [CNECT]
•
HCO 13 – 2016 – Healthcare workforce IT skills [CNECT]
•
HCO 14 – 2016 - EU-US interoperability roadmap [CNECT]
•
HCO 15- 2016 - EU eHealth Interoperability conformity assessment
[CNECT]
•
HCO 16- 2016 – Standardisation needs in the field of ICT for Active
and Healthy Ageing [CNECT]
21
HORIZON PRIZE
• The European Commission has launched the:
Horizon Prize for Better use of Antibiotics
• This challenge prize is offering a cash reward of
€1 million
• To the person or team who can most effectively meet the
following challenge: Develop a rapid test that will allow healthcare
providers to distinguish, at the point-of-care, between patients
with upper respiratory tract infections that require antibiotics and
those that can be treated safely without them
Upper Respiratory Tract Infections include pharyngitis, sinusitis, otitis and bronchitis
22
GLOPID-R
A Global Research Collaboration for
Infectious Disease Preparedness
• A global multifunder initiative
• A network of research funders which aims to
spark a collaborative global research response within 48
hours, after an outbreak
• Key funders from Australia, Brazil, Canada,
China, South Africa, US, France, UK, Sweden,
Spain, Germany
23
GloPID-R objectives
 Facilitate exchange of information
 Address scientific, legal, ethical and financial challenges
 Implement a 'One Health' approach with close
cooperation between human and animal health researchers
 Establish a strategic agenda for research response
 Connect infectious disease research networks
 Create partnerships with low-income countries
24
EDCTP2 (2014 – 2024)
•
Broader scope: support to clinical trials to bring
treatments, vaccines, diagnostics and delivery
optimisation closer to the patients of HIV/AIDS,
TB, malaria and neglected infectious diseases
•
More EU co-funding
€683 million from EU Horizon2020 + at least the
same amount from participating countries
• Governance 28 full member countries: 14
African + 14 European countries
• Publication of work plan 2015
http://www.edctp.org
25
Diseases: HIV/AIDS, TB, Malaria, NIDs, emerging infectious diseases of
particular relevance for Africa, including Ebola
New tools and interventions: Diagnostics, drugs, vaccines and
microbicides
Capacity Development: Fellowships, Networks, Ethics, Regulatory
General rules for participation: At least 2 legal entity in EU Member States
or in countries associated to Horizon 2020 and one legal entity in Sub
Saharan Africa
26
Get prepared!
Free of charge services to assist you:
•
Call text, guide for applicants, FAQs: Participant portal
http://ec.europa.eu/research/participants/portal/desktop/en/home.html
•
Practical information & assistance: National Contact Points (NCPs), Enterprise Europe
Network (EEN)
http://ec.europa.eu/research/participants/portal/desktop/en/support/national_contact_points.ht
ml
•
Find partners, training, brokerage: Fit for Health 2.0
http://www.fitforhealth.eu/
•
Projects funded in FP7 Health: EU Health projects database
http://www.healthcompetence.eu/converis/publicweb/area/1353
•
IP questions and advices: IPR helpdesk
https://www.iprhelpdesk.eu/
•
•
SME regulatory one stop shop: EMA SME office
http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/general_content_000059.jsp
Become evaluator - select the best projects
http://ec.europa.eu/research/participants/portal/desktop/en/experts/index.html
27
Thank you
www.ec.europa/research/horizon2020
http://ec.europa.eu/research/health/infectious-diseases/index_en.html
28